CDK4 and neoplasm: In addition to their effects on DCs, CDK4/6 inhibitors modulate TAMs that are shifted from an M2-like phenotype typically associated with immunosuppression, toward an M1-like phenotype that conversely contributes to anti-tumour immunity [124–128].